{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T17:17:06Z","timestamp":1779124626837,"version":"3.51.4"},"reference-count":180,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The treatment landscape of advanced non-small cell lung cancer (NSCLC) has changed dramatically since the emergence of immune checkpoint inhibitors (ICIs). Although some patients achieve long survival with relatively mild toxicities, not all patients experience such benefits from ICI treatment. There are several ways to use ICIs in NSCLC patients, including monotherapy, combination immunotherapy, and combination chemoimmunotherapy. Decision-making in the selection of an ICI treatment regimen for NSCLC is complicated partly because of the absence of head-to-head prospective comparisons. Programmed death-ligand 1 (PD-L1) expression is currently considered a standard biomarker for predicting the efficacy of ICIs, although some limitations exist. In addition to the PD-L1 tumor proportion score, many other clinical factors should also be considered to determine the optimal treatment strategy for each patient, including age, performance status, histological subtypes, comorbidities, status of oncogenic driver mutation, and metastatic sites. Nevertheless, evidence of the efficacy and safety of ICIs with some specific conditions of these factors is insufficient. Indeed, patients with poor performance status, oncogenic driver mutations, or interstitial lung disease have frequently been set as ineligible in randomized clinical trials of NSCLC. ICI use in these patients is controversial and remains to be discussed. It is important to select patients for whom ICIs can benefit the most from these populations. In this article, we review previous reports of clinical trials or experience in using ICIs in NSCLC, focusing on several clinical factors that are associated with treatment outcomes, and then discuss the optimal ICI treatment strategies for NSCLC.<\/jats:p>","DOI":"10.3389\/fonc.2022.952393","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:20:37Z","timestamp":1660314037000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors"],"prefix":"10.3389","volume":"12","author":[{"given":"Natsuki","family":"Nakagawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy041","article-title":"Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases","volume":"29","author":"Vokes","year":"2018","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1917346","article-title":"Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC","volume":"383","author":"Herbst","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1910231","article-title":"Nivolumab plus ipilimumab in advanced non-Small-Cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/S1470-2045(20)30641-0","article-title":"First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial","volume":"22","author":"Paz-Ares","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-Small-Cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.07.009","article-title":"IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous NSCLC","volume":"16","author":"Socinski","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/J.ESMOOP.2021.100273","article-title":"First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update","volume":"6","author":"Reck","year":"2021","journal-title":"ESMO Open"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: Atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1\u2013selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189","volume":"32","author":"Rodr\u00edguez-Abreu","year":"2021","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/J.JTHO.2021.09.010","article-title":"First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial","volume":"17","author":"Paz-Ares","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: Pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-Small-Cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2020.06.015","article-title":"A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: Protocol-specified final analysis of KEYNOTE-407","volume":"15","author":"Paz-Ares","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.035","article-title":"Strategies to overcome resistance to immune checkpoint blockade in lung cancer","volume":"154","author":"Attili","year":"2021","journal-title":"Lung Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2021.03.199","article-title":"Immunotherapy use outside clinical trial populations: never say never","volume":"32","author":"Rzeniewicz","year":"2021","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLLC.2018.05.014","article-title":"Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials","volume":"19","author":"Kawachi","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/JTO.0B013E3181FB50D8","article-title":"Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials","volume":"6","author":"Baggstrom","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3747\/CO.25.3978","article-title":"Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients","volume":"25","author":"Al-Baimani","year":"2018","journal-title":"Curr Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-130","article-title":"Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials","volume":"9","author":"Vardy","year":"2009","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(21)00228-2","article-title":"Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial","volume":"397","author":"Sezer","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 tria","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANNONC.2021.06.004","article-title":"Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer","volume":"32","author":"Sugawara","year":"2021","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non\u2013Small-Cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0237","article-title":"Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial","volume":"6","author":"Rizvi","year":"2020","journal-title":"JAMA Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03579","article-title":"Pembrolizumab plus ipilimumab or placebo for metastatic non\u2013Small-Cell lung cancer with PD-L1 tumor proportion score \u2265 50%: Randomized, double-blind phase III KEYNOTE-598 study","volume":"39","author":"Boyer","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: Results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz288","article-title":"Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression","volume":"30","author":"Aguilar","year":"2019","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cllc.2020.10.002","article-title":"Differential efficacy of pembrolizumab according to metastatic sites in patients with PD-L1 strongly positive (TPS \u2265 50%) NSCLC","volume":"22","author":"Takeyasu","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00843-y","article-title":"Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)","volume":"37","author":"Tamiya","year":"2019","journal-title":"Invest New Drugs"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1080\/14737159.2021.1920396","article-title":"An update on companion and complementary diagnostic assays for PD-1\/PD-L1 checkpoint inhibitors in NSCLC","volume":"21","author":"J\u00f8rgensen","year":"2021","journal-title":"Expert Rev Mol Diagn"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.208","article-title":"How low can you go? PD-L1 expression as a biomarker in trials of cancer immunotherapy","volume":"32","author":"Fundytus","year":"2021","journal-title":"Ann Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet (London England)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet (London England)"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.04.026","article-title":"Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC","volume":"15","author":"Hong","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.annonc.2020.01.065","article-title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","volume":"31","author":"Schoenfeld","year":"2020","journal-title":"Ann Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-018-1305-4","article-title":"Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments","volume":"23","author":"Omori","year":"2018","journal-title":"Int J Clin Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-38068-3","article-title":"Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC","volume":"9","author":"Jiang","year":"2019","journal-title":"Sci Rep"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00903-w","article-title":"Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer","volume":"35","author":"Wu","year":"2022","journal-title":"Mod Pathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.03.028","article-title":"Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial","volume":"15","author":"Jotte","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.7629","article-title":"Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non\u2013small-cell lung cancer","volume":"35","author":"Govindan","year":"2017","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/S41379-020-0644-7","article-title":"Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)","volume":"34","author":"de Ruiter","year":"2021","journal-title":"Mod Pathol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: Results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.011","article-title":"Efficacy of immune checkpoint inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC)","volume":"14","author":"Jeanson","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2017.1396403","article-title":"Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1\/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials","volume":"7","author":"Huang","year":"2018","journal-title":"Oncoimmunology"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2021.0546","article-title":"Association between KRAS variant status and outcomes with first-line immune checkpoint inhibitor-based therapy in patients with advanced non-Small-Cell lung cancer","volume":"7","author":"Sun","year":"2021","journal-title":"JAMA Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-0429","article-title":"Disparities in prostate, lung, breast, and colorectal cancer survival and comorbidity status among urban American indians and alaskan natives","volume":"77","author":"Emerson","year":"2017","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discovery"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359211006950","article-title":"KRAS\/LKB1 and KRAS\/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas","volume":"13","author":"Gu","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non\u2013small cell lung cancer\u2013a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.ccr-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin\u2013pemetrexed for EGFR -mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.lungcan.2017.11.009","article-title":"Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions","volume":"115","author":"Soo","year":"2018","journal-title":"Lung Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: Dusk or dawn","volume":"16","author":"Qiao","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30144-X","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-Small-Cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol"},{"key":"B78","unstructured":"2022"},{"key":"B79","unstructured":"UMIN-CTR2019"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): An open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"TATTON: a multi-arm, phase ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M\u2013positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Chih-Hsin Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation \u2014 positive advanced non\u2013small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6065","article-title":"Systemic therapy for stage IV non\u2013Small-Cell lung cancer: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Hanna","year":"2017","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/S10147-019-01431-Z","article-title":"The Japanese lung cancer society guideline for non-small cell lung cancer, stage IV","volume":"24","author":"Akamatsu","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03329-0","article-title":"Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression","volume":"147","author":"Masuda","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/J.BBRC.2015.05.030","article-title":"EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-\u03baB","volume":"463","author":"Lin","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000500","article-title":"Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: Implication for optional immune targeted therapy for NSCLC patients with EGFR mutation","volume":"10","author":"Chen","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000500","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3390\/IJMS20153821","article-title":"Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC)","volume":"20","author":"Hsu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B100","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10644","article-title":"Prognostic effect of liver metastasis in lung cancer patients with distant metastasis","volume":"7","author":"Ren","year":"2016","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-019-03104-w","article-title":"The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases","volume":"146","author":"Kitadai","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12779","article-title":"Clinical characteristics of liver metastasis in nivolumabtreated patients with non-small cell lung cancer","volume":"38","author":"Shiroyama","year":"2018","journal-title":"Anticancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2239-4","article-title":"Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)","volume":"67","author":"Schmid","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1823779","article-title":"Metastatic sites as predictors in advanced NSCLC treated with PD-1 inhibitors: a systematic review and meta-analysis","volume":"17","author":"Huang","year":"2021","journal-title":"Hum Vaccines Immunother"},{"key":"B107","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/NI.2691","article-title":"Immune surveillance by the liver","volume":"14","author":"Jenne","year":"2013","journal-title":"Nat Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/J.JAUT.2015.08.020","article-title":"Immunity, tolerance and autoimmunity in the liver: A comprehensive review","volume":"66","author":"Doherty","year":"2016","journal-title":"J Autoimmun"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0460","article-title":"Role of the microenvironment in liver metastasis: From pre- to prometastatic niches","volume":"22","author":"Brodt","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/1078-0432.ccr-21-1193","article-title":"The liver\u2013immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"34","DOI":"10.21037\/atm-20-1471","article-title":"Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases","volume":"9","author":"Qiao","year":"2021","journal-title":"Ann Transl Med"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTARC.2020.100290","article-title":"Analysis of bevacizumab treatments and metastatic sites of lung cancer","volume":"26","author":"Sato","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/NM0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1007\/S00262-007-0441-X","article-title":"The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients","volume":"57","author":"Osada","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/JIMMUNOL.181.1.346","article-title":"Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma","volume":"181","author":"Kusmartsev","year":"2008","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-020-07206-4","article-title":"Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: A systematic review and meta-analysis","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/S10120-018-00922-8","article-title":"Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer","volume":"22","author":"Sasaki","year":"2019","journal-title":"Gastric Cancer"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11111699","article-title":"Hyperprogressive disease during anti-PD-1 (PDCD1) \/ PD-L1 (CD274) therapy: A systematic review and meta-analysis","volume":"11","author":"Kim","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: Analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0360-3016(80)90195-9","article-title":"The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group","volume":"6","author":"Borgelt","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.008","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"15","author":"Pillai","year":"2018","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/J.JTHO.2021.06.020","article-title":"Outcomes with pembrolizumab plus platinum-based chemotherapy for patients with NSCLC and stable brain metastases: Pooled analysis of KEYNOTE-021, -189, and -407","volume":"16","author":"Powell","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: Pembrolizumab versus platinum-based chemotherapy for advanced non\u2013small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1724953","article-title":"Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving nivolumab","volume":"20","author":"Pantano","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00520-1","article-title":"Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC","volume":"18","author":"Grant","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/17588359211018537","article-title":"Selection of optimal first-line immuno-related therapy based on specific pathological characteristics for patients with advanced driver-gene wild-type non-small cell lung cancer: a systematic review and network meta-analysis","volume":"13","author":"Sheng","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.5453","article-title":"Prognostic impact of minimal pleural effusion in non - small-cell lung cancer","volume":"32","author":"Ryu","year":"2014","journal-title":"J Clin Oncol"},{"key":"B131","first-page":"47","article-title":"Prognostic value of pleural effusion in patients with non-small-cell lung cancer","volume":"3","author":"Sugiura","year":"1997","journal-title":"Clin Cancer Res"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0B013E318267223A","article-title":"Prognostic impact of malignant pleural effusion at presentation in patients with metastatic non-small-cell lung cancer","volume":"7","author":"Morgensztern","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12885-020-6582-4","article-title":"Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab","volume":"20","author":"Morita","year":"2020","journal-title":"BMC Cancer"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2807","article-title":"Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status","volume":"9","author":"Adachi","year":"2020","journal-title":"Cancer Med"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00882-5","article-title":"Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non\u2013small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study","volume":"38","author":"Kawachi","year":"2020","journal-title":"Invest New Drugs"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100355","article-title":"Efficacy of immune checkpoint inhibitor with or without chemotherapy for nonsquamous NSCLC with malignant pleural effusion: A retrospective multicenter cohort study","volume":"3","author":"Kawachi","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1554969","article-title":"Making cold malignant pleural effusions hot: driving novel immunotherapies","volume":"8","author":"Murthy","year":"2019","journal-title":"Oncoimmunology"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14710","article-title":"Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non\u2013small cell lung cancer","volume":"112","author":"Saito","year":"2021","journal-title":"Cancer Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/NRC2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/J.SEMCANCER.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/S00280-012-2026-4","article-title":"Bevacizumab plus chemotherapy for advanced non-squamous non-small-cell lung cancer with malignant pleural effusion","volume":"71","author":"Kitamura","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/S12032-013-0676-7","article-title":"Phase2 study of bevacizumab with carboplatin-paclitaxel for non-small cell lung cancer with malignant pleural effusion","volume":"30","author":"Tamiya","year":"2013","journal-title":"Med Oncol"},{"key":"B143","article-title":"Vascular endothelial growth factor in plasma and pleural effusion is a biomarker for outcome after bevacizumab plus carboplatin-paclitaxel treatment for non-small cell lung cancer with malignant pleural effusion","volume":"36","author":"Tamiya","year":"2016","journal-title":"Anticancer Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13472","article-title":"Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study north East Japan study group trial NEJ013B","volume":"11","author":"Noro","year":"2020","journal-title":"Thorac Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1053\/J.SEMINONCOL.2018.08.007","article-title":"FDA Analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1\/PD-L1 blocking antibodies","volume":"45","author":"Marur","year":"2018","journal-title":"Semin Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/S40425-018-0336-8","article-title":"Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis","volume":"6","author":"Elias","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B147","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.lungcan.2019.08.030","article-title":"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer","volume":"137","author":"Galli","year":"2019","journal-title":"Lung Cancer"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15750","article-title":"Immune checkpoint inhibitors in real-world treatment of older adults with non\u2013small cell lung cancer","volume":"67","author":"Muchnik","year":"2019","journal-title":"J Am Geriatr Soc"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2021.4960","article-title":"Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: A multicenter international cohort study","volume":"7","author":"Nebhan","year":"2021","journal-title":"JAMA Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.010","article-title":"Safety, efficacy, and patient-reported health-related quality of life and symptom burden with nivolumab in patients with advanced non\u2013small cell lung cancer, including patients aged 70 years or older or with poor performance status (CheckMate 153)","volume":"14","author":"Spigel","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B151","unstructured":"European Medical agenc2022"},{"key":"B152","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/J.LUNGCAN.2021.08.015","article-title":"Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer","volume":"161","author":"Morimoto","year":"2021","journal-title":"Lung Cancer"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70259-0","article-title":"Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review","volume":"13","author":"Hamaker","year":"2012","journal-title":"Lancet Oncol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1001\/JAMAONCOL.2020.6736","article-title":"Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: A systematic review","volume":"7","author":"Garcia","year":"2021","journal-title":"JAMA Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.21037\/JTD.2017.09.51","article-title":"Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC group","volume":"9","author":"Le Caer","year":"2017","journal-title":"J Thorac Dis"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0796","article-title":"Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer","volume":"29","author":"Kanesvaran","year":"2011","journal-title":"J Clin Oncol"},{"key":"B157","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/IJC.10882","article-title":"Impact of comorbidity on lung cancer survival","volume":"103","author":"Tammemagi","year":"2003","journal-title":"Int J Cancer"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8","article-title":"Outcome of patients with a performance status of 2 in Eastern cooperative oncology group study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma","volume":"92","author":"Sweeney","year":"2001","journal-title":"Cancer"},{"key":"B160","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2019.11.019","article-title":"CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations","volume":"127","author":"Felip","year":"2020","journal-title":"Eur J Cancer"},{"key":"B162","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S2213-2600(20)30033-3","article-title":"Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial","volume":"8","author":"Middleton","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S301500","article-title":"Anti-PD-1 monotherapy for advanced NSCLC patients with older age or those with poor performance status","volume":"14","author":"Matsubara","year":"2021","journal-title":"Onco Targets Ther"},{"key":"B164","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2013a systematic review and meta-analysis of real world data","volume":"145","author":"Dall\u2019Olio","year":"2020","journal-title":"Lung Cancer"},{"key":"B165","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non-small cell lung cancer treated with pembrolizumab monotherapy","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B166","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.ejrad.2015.01.021","article-title":"Interstitial lung abnormalities in treatment-na\u00efve advanced non-small-cell lung cancer patients are associated with shorter survival","volume":"84","author":"Nishino","year":"2015","journal-title":"Eur J Radiol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12759","article-title":"Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease","volume":"9","author":"Kanai","year":"2018","journal-title":"Thorac Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/J.LUNGCAN.2018.10.001","article-title":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis","volume":"125","author":"Yamaguchi","year":"2018","journal-title":"Lung Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/J.RESINV.2019.05.002","article-title":"Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer","volume":"57","author":"Nakanishi","year":"2019","journal-title":"Respir Investig"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2974","article-title":"Prognostic significance of the radiologic features of pneumonitis induced by anti-PD-1 therapy","volume":"9","author":"Watanabe","year":"2020","journal-title":"Cancer Med"},{"key":"B171","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1136\/THORAXJNL-2015-207252","article-title":"Interobserver agreement for the ATS\/ERS\/JRS\/ALAT criteria for a UIP pattern on CT","volume":"71","author":"Walsh","year":"2016","journal-title":"Thorax"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJRO.2020.100228","article-title":"Interobserver variability in high-resolution CT of the lungs","volume":"7","author":"Widell","year":"2020","journal-title":"Eur J Radiol Open"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.08.018","article-title":"A phase 2 study of atezolizumab for pretreated NSCLC with idiopathic interstitial pneumonitis","volume":"15","author":"Ikeda","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318216ee6b","article-title":"The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer","volume":"6","author":"Kenmotsu","year":"2011","journal-title":"J Thorac Oncol"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2019.06.001","article-title":"Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial","volume":"134","author":"Fujimoto","year":"2019","journal-title":"Lung Cancer"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer a systematic review and meta-analysis supplemental content","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/J.CHEST.2017.04.177","article-title":"Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of trials","volume":"152","author":"Khunger","year":"2017","journal-title":"Chest"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379","article-title":"Toxicities of immunotherapy for the practitioner","volume":"33","author":"Weber","year":"2015","journal-title":"J Clin Oncol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113245","article-title":"Blood biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer","volume":"11","author":"Alfranca","year":"2022","journal-title":"J Clin Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.952393\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:20:45Z","timestamp":1660314045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.952393\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":180,"alternative-id":["10.3389\/fonc.2022.952393"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.952393","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"article-number":"952393"}}